OrbiMed Advisors sells Corvus Pharma (CRVS) shares worth $4.89 million

Published 02/07/2025, 02:34
OrbiMed Advisors sells Corvus Pharma (CRVS) shares worth $4.89 million

OrbiMed Advisors LLC, a major shareholder in Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS), sold 1,176,332 shares of common stock on June 27, 2025, for approximately $4.89 million. The shares were sold at a price of $4.1586. According to InvestingPro data, CRVS has delivered an impressive 117% return over the past year, despite currently trading at $3.86, below OrbiMed’s sale price.

On the same day, OrbiMed also acquired 1,397,684 shares of Corvus Pharmaceuticals through the exercise of common warrants at a price of $3.50, for a total value of $4.89 million.

Following these transactions, OrbiMed Advisors now holds 7,165,006 shares of Corvus Pharmaceuticals. These securities are held by OrbiMed Private Investments V, LP, of which OrbiMed Capital GP V LLC is the general partner, and OrbiMed Advisors LLC is the managing member.

In other recent news, Corvus Pharmaceuticals has released promising interim data from its Phase 1 clinical trial for soquelitinib, a drug under investigation for treating moderate to severe atopic dermatitis. The trial results indicate that cohort 3, which received a higher dose, showed a more significant improvement in symptoms compared to earlier cohorts and the placebo group. The 200 mg twice-daily dosage demonstrated a 64.8% reduction in the Eczema Area and Severity Index score at day 28. Safety data suggests that soquelitinib is well-tolerated with no significant toxicities. In a related development, Angel Pharmaceuticals, Corvus’s partner in China, has received approval to begin a Phase 1b/2 trial of soquelitinib in China. Meanwhile, Cantor Fitzgerald reiterated an Overweight rating on Corvus, expressing a positive outlook on the company’s novel treatment approach. Mizuho (NYSE:MFG) Securities adjusted its price target for Corvus, reducing it to $11 but maintained an Outperform rating, highlighting the drug’s potential as a convenient treatment option. Oppenheimer analyst Jeff Jones also maintained an Outperform rating and raised the price target from $2 to $17, citing the promising clinical-stage programs of Corvus.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.